endocrinology
Bone health

Denosumab discontinuation: the more you gain the more you lose?

Up to one in five patients on denosumab therapy show losses in bone mineral density (BMD) when they switch to a bisphosphonate after a year, research has shown. A study that followed 115 postmenopausal women who completed 12 months of denosumab therapy (60 mg every 6 months) found that most maintained the BMD gains when ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic